Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Sanofi SA — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.5 (market cap $16.72B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 5.7× iShares 3 7 Year Treasury Bond ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Sanofi SA for 94 Days on average.
| IEI | SNY | |
|---|---|---|
Market Cap | $16.72B | $95.18B |
Volume | 3,963,319 | 2,995,646 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $52.34 |
52-Week Low | $113.17 | $39.51 |
Typical Hold Time | 43 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI trades at $113.465 with minimal daily movement (+0.07%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces resistance at $114 with support at $113. Recent dividend payments of $0.37-0.38 demonstrate consistent shareholder returns, though key financial ratios remain unavailable for fundamental assessment.
The bearish technical outlook and lack of fundamental data create uncertainty. Bond market volatility and rising Treasury yields present macroeconomic headwinds. Investment potential depends on forthcoming financial disclosures and the company's ability to navigate current interest rate environment.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
